1. Home
  2. CCEL vs VTGN Comparison

CCEL vs VTGN Comparison

Compare CCEL & VTGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cryo-Cell International Inc.

CCEL

Cryo-Cell International Inc.

N/A

Current Price

$3.35

Market Cap

30.9M

Sector

Health Care

ML Signal

N/A

Logo VistaGen Therapeutics Inc.

VTGN

VistaGen Therapeutics Inc.

HOLD

Current Price

$0.70

Market Cap

25.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CCEL
VTGN
Founded
1989
1998
Country
United States
United States
Employees
76
41
Industry
Managed Health Care
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
30.9M
25.3M
IPO Year
2022
2014

Fundamental Metrics

Financial Performance
Metric
CCEL
VTGN
Price
$3.35
$0.70
Analyst Decision
Hold
Hold
Analyst Count
1
3
Target Price
N/A
$0.90
AVG Volume (30 Days)
3.2K
952.5K
Earning Date
04-14-2026
06-16-2026
Dividend Yield
4.26%
N/A
EPS Growth
N/A
N/A
EPS
0.01
N/A
Revenue
$25,384,279.00
N/A
Revenue This Year
N/A
$124.49
Revenue Next Year
N/A
$353.99
P/E Ratio
$384.00
N/A
Revenue Growth
9.76
N/A
52 Week Low
$2.72
$0.43
52 Week High
$5.43
$5.14

Technical Indicators

Market Signals
Indicator
CCEL
VTGN
Relative Strength Index (RSI) 42.84 60.50
Support Level $3.02 $0.52
Resistance Level $3.92 $0.77
Average True Range (ATR) 0.20 0.07
MACD -0.00 0.01
Stochastic Oscillator 21.51 82.57

Price Performance

Historical Comparison
CCEL
VTGN

About CCEL Cryo-Cell International Inc.

Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.

About VTGN VistaGen Therapeutics Inc.

Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.

Share on Social Networks: